GO
Loading...

Pharmaceuticals

More

  • *Otsuka Holdings dives to more than 1- month low after M&A news. TOKYO, Dec 3- Japan's Nikkei share average rose to a more than seven-year high on Wednesday after Wall Street gained and the dollar hit a fresh seven-year high against the yen, but Otsuka Holdings tumbled on news that it will buy a U.S. drugmaker for about $3.5 billion. "It is possible that the market may...

  • LONDON, Nov 30- GlaxoSmithKline will this week inform U.S. staff of hundreds of job cuts in its biggest market as the drugmaker starts implementing a major cost-saving programme, sources familiar with the matter said on Sunday. Britain's top drugmaker announced at third-quarter results on Oct. 22 that the new restructuring scheme would save 1 billion pounds in...

  • AstraZeneca on failed Pfizer deal  Friday, 28 Nov 2014 | 4:35 AM ET

    The tax inversion announcement seriously reduced the likelihood of the Pfizer AstraZeneca deal going ahead says CNBC's Catherine Boyle.

  • Pascal Soriot, CEO of Astrazeneca, says there will be less need for mergers and acquisitions as the company's internal drug pipeline is strong.

  • I'm a strong believer in Europe: Astrazeneca CEO  Friday, 28 Nov 2014 | 2:45 AM ET

    Discussing a possible British exit from the European Union, Pascal Soriot, CEO of Astrazeneca, says he is a believer in Europe and immigration is key to getting the best talent for his company.

  • Astrazeneca could eye tech firms for M&A: Expert  Friday, 28 Nov 2014 | 2:30 AM ET

    Mike Ward, global director of content at SCRIP Intelligence, says pharmaceutical companies could look towards the technology sector for interesting mergers, acquisitions or partnerships.

  • Pfizer deal would have failed: Astrazeneca CEO  Friday, 28 Nov 2014 | 1:05 AM ET

    Pfizer's bid to take over U.K. pharmaceutical company AstraZeneca would have probably "fallen apart", Pascal Soriot, the firm's CEO, told CNBC.

  • Teva Pharma names Peterburg new chairman Wednesday, 26 Nov 2014 | 1:39 PM ET

    Nov 26- The board of Teva Pharmaceutical Industries Ltd elected Yitzhak Peterburg as its chairman, succeeding Phillip Frost, who is due to step down at the end of the year. The company also appointed Sol Barer, the former chief executive of Celgene Corp, as a director. Teva stock was up 0.8 percent at $57.02 on the New York Stock Exchange.

  • Bristol-Myers said it had initially sought permission from the U.S. Food and Drug Administration to market the drug, a so-called NS5A inhibitor, in combination with asunaprevir, one of the New York- based company's experimental medicines. But Bristol-Myers abandoned its U.S. marketing application for asunaprevir in October because of potential...

  • Pfizer to join forces with AstraZeneca?  Wednesday, 26 Nov 2014 | 4:35 AM ET

    American pharmaceutical giant has been pursuing AstraZeneca for some time, however CNBC's Catherine Boyle says it looks like the deal has "definitely receded".

  • Pfizer to renew pursuit of AstraZeneca?  Wednesday, 26 Nov 2014 | 1:20 AM ET

    Pfizer has seen off its six month cooling period before it can launch another bid for AstraZeneca, but will the American drugs giant continue its pursuit?

  • Searching for relief from expensive generic drugs Tuesday, 25 Nov 2014 | 2:24 PM ET
    Senator Amy Klobuchar

    Generic drug costs have risen so much that some drugs have surpassed their equivalents in other developed countries, the New York Times reports.

  • Fighting kids' cancer... fixing a broken system  Friday, 21 Nov 2014 | 6:49 AM ET

    CNBC's Meg Tirrell, and Nancy Goodman, Kids v. Cancer founder, discuss the initiative to encourage drug companies to develop treatments for children with cancer and other rare diseases.

  • How to get cancer drugs to kids: A mother's take Friday, 21 Nov 2014 | 6:00 AM ET
    The Froman family, including Nancy Goodman, Mike Froman, and kids Ben and Sarah. They hold a photo of Jacob, who died of medulloblastoma, a rare form of brain cancer, at age 10.

    Kids facing cancer need access to promising — albeit unapproved — drugs, say these parents, who have faced the battle with their children firsthand.

  • Sanofi: Wouldn't trade our pipeline  Thursday, 20 Nov 2014 | 1:47 PM ET

    Sanofi's global R&D President Dr. Elias Zerhouni, says he wouldn't trade his company's pipeline with anybody in the industry, and discusses the upcoming drug launches.

  • Nov 20- A U.S. court has denied a request by Indian drugmaker Ranbaxy Laboratories Ltd to stop competitors from launching copies of AstraZeneca Plc's heartburn pill Nexium and Roche's antiviral, a court filing showed. Ranbaxy had filed a lawsuit against the U.S. Food and Drug Administration last week for revoking tentative approvals it gave the company to make...

  • Nov 20- A U.S. court has denied a request by Indian drugmaker Ranbaxy Laboratories Ltd to stop competitors from launching copies of AstraZeneca Plc's heartburn pill Nexium and Roche's antiviral Valcyte, a court filing showed. Ranbaxy had sought the restraining order against Dr Reddy's Laboratories and U.S. firm Endo International Plc in a lawsuit it filed...

  • Nov 20- Global pharmaceutical spending will break the trillion dollar mark in 2014, driven by high prices in the United States for novel treatments such as Gilead Sciences Inc's Sovaldi for hepatitis C and new cancer drugs, according to a study released on Thursday. Total spending on drugs will hit $1.06 trillion, an increase of 7 percent over 2013 levels,...

  • Nov 18- The estimated average cost of developing an approved new drug has more than doubled to more than $2.5 billion from a 2003 estimate by Tufts University, but critics questioned the figure and noted the school's strong financial ties to the pharmaceutical industry. The Tufts Center for the Study of Drug Development, located in Boston, in 2003 estimated the...

  • AstraZeneca trumpets strength in drug development Tuesday, 18 Nov 2014 | 3:24 AM ET
    British pharmaceutical company AstraZeneca's manufacturing site in Macclesfield, northwest England.

    AstraZeneca said it had made good progress in developing a pipeline of new drugs.